Eli Lilly is trading 3.6% down now at $1189.33, extending weakness after declines on August 25 and August 24.
- Eli Lilly reported a positive August 26 update linking Zepbound with lower healthcare costs.
- Available coverage identifies no new negative company catalyst and does not explicitly connect the announcement to the decline.
- No confirmed earnings, regulatory, or analyst event was found.